Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Manchester Genetics > Treatment Of Genetic Disease > Flashcards

Treatment Of Genetic Disease Flashcards

You may prefer our related Brainscape-certified flashcards:
Biology 101 flashcards
1
Q

What makes a genetic disease treatable?

A

Diseases where a see relatable protein can be taken up by and complement other cells
Disease where defect is membrane protein, can to raffia to its site of action or into correct cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is a lysosomal storage disease?

A

Cell produces substrate for use within or outside cells
Internalised and broken down ( possibly in lysosomes)
Lack of enzyme or protein leads to accumulation of undegraded substrates in lysosomes
Can affect brain, bones, joints, muscles and other organs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Outline the principle of cross correction

A

Lysosomal enzymes are glycosylated in the ER
Have a secretory signal and are further modified in the Golgi with M-6-P
M-6-P receptors target them to lysosomes where acidic pH activates them
Some are secreted
Receptors on cell surface pick them up and traffic through endoscopes to lysosomes to be activated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the treatments for LSDs?

A

Enzyme replacement therapy (ERT)
Haematopoietic stem cell transplant (HSCT)
Substrate reduction therapy (SRT)
Genetic therapy (GT)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How does ERT work?

A

Enzyme delivered to blood steam can be take up by affected cells and correct disease
BBB limits delivery to brain and makes it ineffectual for neuronopathicdisease
Won’t work in LSDs where enzyme not secreted
Mammalian cells lines used for correct M-6-P tags

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the limitations?

A 
£144,000/patient/year in UK 
EARLIER TREATMENT BETTER 
BBB 
Joints and growth plate of bone poorly connected to blood stream 
M6P slow compared to MR 
Antibody response
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is future of ERT?

A

Bypass barrier by physical injection
Never production of enzyme or drug may improve delivery
Modify enzymes to improve uptake
Tolerisation regiment to limit antibody response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Outline HSCT

A

Delivery of enzyme from blood cells
Monocytes enter brain and release enzyme
HSCT donor cells repopulate blood system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the limitations of HSCT?

A

Early intervention essential
Few LSDs implicated as treatable this way
Some risk of morbidity/mortality
Insufficient brain enzyme produced in some diseases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Outline SRT

A

Reduction of primary storage material or restoring down alternate pathways
Drugs must reduce without being toxic
Drug must be able to reach all affected cells including brain
Not likely to raise antibody response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Discuss an example SRT for Gaucher

A

Miglustat
Immunosugar inhibiting glicosylceramide synthase
Blocks first step in glycosphingolipid production
Developed as treatment to Gaucher type 1 : reduces phosphosphingolipids
Also used for niemann pick C patients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Discuss an example SRT for muccopolysaccharidosis

A 
Genistein
Tyrosine kinase inhibitor 
Purified from soy beans 
Blocks GAG production 
10% crosses BBB
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are the limitations of SRT?

A

Reduction of substrate can never cure disease
Primarily delays symptom onset
Low drug toxicity and BBB permeability essential

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the four types of gene therapy?

A

Gene addition
Gene repair
Gene inhibition
Cell killing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Outline gene addition

A

Remove viral genes and package RNA/DNA therapeutic gene and promoter in their place
Can be episomal from a plasmid or more stable from viral vector or integration into host genome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are barriers to gene addition?

A

Body resists entry vis skin, immune system, membrane, BBB etc.

17
Q

What are the two routes of delivery?

A

Direct - intravenous, intracranial, intraventricular or intraocular. Targeting specificity achieved by deluxe site. AAV main choice due to high titres. Limites= immunogenicity, pre existing immunity and scale up

Ex Vivo- transduce cells in lab and them reintroduce as stem cells. Lenti viral vectors. Unlimited self renewal. Limitations= require space to re-engraft and hence damage target organs to achieve it

18
Q

What are AAV?

A 
Adeno-associated viral vectors 
Simple ssDNA 
More than 10 serotypes that can infect different tissues
Replace viral genes with therapeutic transgene and promoter to stop replication 
Small packaging capacity
Mostly remain outside nucleus 
 Great for immune privileged sites 
AAV9 can cross BBB
Immune response common
19
Q

How have AAV gene therapies been used?

A

Haemophilia B = AAV8 against severe factor IX deficiency. Steady state of 1-6% of normal levels achieved.
Sanfillippo disease IIIA/B = direct Brian injection. Shows stabilisation of disease and improvement with more injections
Batten disease = brain injection. Stabilisation in some patients
Parkinson disease = brain ejection. 23% improvement in treated vs 12% in non-treated
Blindness= inject to eye. Visual improvement. Vector persists as eye is immune privileged site.

20
Q

What are retrovirus/lentiviral vectors?

A

RNA viral genome
Reverse transcription and random integration
Can infect stem cells
Viral envelope provides specificity for cell types
Vector creation - replace viral genes with therapeutic ones. Removes LTRs and replace with SIN vectors. Replace promoter with CMV and remove ability to replicate.

21
Q

Where have retro/lentiviral vectors been used?

A

HSC Gene therapy for immunodeficiency

Limited to patients with no other therapy options and no donor available

22
Q

How could gene repair be achieved?

A

Zinc finger nucleases, transcription activator-like effector nucleases (TALEN), CRISPR/Cas9 guided endonuclease system

All introduce DS break at targeted location with the guide of homologous binding proteins or RNA

23
Q

What are the future options?

A 
Increase enzyme delivery target organs 
Novel substrate inhibitors 
STOP codon read through 
Antiinflamatories 
Gene theory clinical trials
Combination therapies
24
Q

What can be targeted in treatment of genetic disease?

A

Protein Function
Protein translation
mRNA
DNA

25
Q

What is non-sense suppression?

A

Nonsense mutations cause nonsense mediated decay
Amino glycosides can suppress the effect by inducing incorporation of random amino acid to achieve read through
Used in cystic fibrosis
Limitations : not able to restore protein function if the aa is essential
Efficiency of read through varies depending on nature of STOP a codon
Read through of a physiological STOP codon could be detrimental

26
Q

How can RNA be targeted?

A

Manipulation of splicing - exon skipping

RNA interference

27
Q

How has exon skipping been used?

A

Treatment of DMD

Skip exon 3 to produce BMD protein - not as detrimental

28
Q

What is RNAi?

A

Natural physiological sequence-specific gene silencing phenomenon mediated by double stranded RNA
miRNA and siRNA are essential

29
Q

How has RNAi been implemented?

A

Retinitis pigmentosa
GCAP1 mutations cause RP
Target mutant product with siRNA in mice to rescue function of retina

30
Q

What are challenges of siRNA?

A

Specificity
Delivery
Duration of silencing

31
Q

What types of gene treatments exist?

A

Genome editing

Gene therapy

32
Q

What three platforms exist for genome editing?

A

Zinc finger nucleases
Transcription activator like effector nucleases
Clustered regulatory inter spaced Short palindromic repeats/CRISPR associated protein 9 (CRISPR/Cas9)

33
Q

What are ZFNs?

A

Artificial restriction enzymes
Fusion protein with Zinc finger domain that is targeted for specific DNA sequences
3amino acid recognise a single base and cleavage domain forms DSB for NHEJ or HR

34
Q

What are TALENs?

A

Fusion protein with TAL effector DNA binding domain
Stretch of diresidues that can target specific sequence
Cleavage domain forms DSB

35
Q

What is CRISPR/Cas9?

A

Originated in bacteria as defence against phage
Guide RNA is designed for recognising site and Cas9 is used to generate DSB
Cas9 requires crRNA and trancRNA to function. Chimeric crRNA and trancRNA form gRNA

36
Q

What four factors are used for iPSC?

A

Oct4, sox2, KLF4 and c-Myc

Manchester Genetics (8 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions